Intrinsiqq
Acumen Pharmaceuticals, Inc. logo

Acumen Pharmaceuticals, Inc. Insider Trading

ABOS

Compare
Last 12 months

Insiders sold 626K and bought nothing on the open market.

86% of the selling was scheduled in advance under 10b5-1 plans. Director Derrell Porter sold 75K on Jun 17, 48% of their stake, outside a plan. The last open-market buy by an executive or director was in Jul 2021.

Net open-market
−626K
0 buys · 21 sales
Under a 10b5-1 plan
86%
of the value sold
Insiders who bought / sold
0 / 9
executives and directors
Last open-market buy
Jul 2021
Jul 6, 2021

Get an email when ABOS's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Jun 15 – 17No plan
    Derrell Porter
    Director · sold 32,300 at avg $2.33
    75K
    48% of stake
  • Jun 9No plan
    Nathan B Fountain
    Director · sold 6,400 at $2.23
    14K
    12% of stake
  • Mar 610b5-1 plan
    Derek M Meisner
    Chief Legal Officer & Corp Sec · sold 2,090 at $3.26
    7K
    1.2% of stake
  • Feb 2710b5-1 plan
    Derek M Meisner
    Chief Legal Officer & Corp Sec · sold 9,406 at $3.01
    28K
    5.1% of stake
  • Jan 26 – 2810b5-1 plan
    Derek M Meisner
    Chief Legal Officer & Corp Sec · sold 17,756 at avg $3.00
    53K
    9.3% of stake
  • Jan 21 – 2310b5-1 plan
    Derek M Meisner
    Chief Legal Officer & Corp Sec · sold 8,934 at avg $1.87
    17K
    4.9% of stake
  • Jan 21 – 2210b5-1 plan
    Eric Siemers
    Chief Medical Officer · sold 3,226 at avg $1.81
    6K
    1.2% of stake
  • Jan 21 – 2210b5-1 plan
    Matt Zuga
    CFO & Chief Business Officer · sold 4,160 at avg $1.83
    8K
    1.3% of stake
  • Jan 21 – 2210b5-1 plan
    Daniel Joseph Oconnell
    Chief Executive Officer · sold 12,035 at avg $1.83
    22K
    1.3% of stake
  • Jan 21 – 2210b5-1 plan
    Russell Barton
    Chief Operating Officer · sold 2,777 at avg $1.81
    5K
    1.3% of stake
  • Jan 8 – 1210b5-1 plan
    Derek M Meisner
    Chief Legal Officer & Corp Sec · sold 50,659 at avg $1.80
    91K
    38% of stake
  • Jan 8 – 1210b5-1 plan
    Daniel Joseph Oconnell
    Chief Executive Officer · sold 26,472 at avg $1.77
    47K
    4.3% of stake
  • Jan 810b5-1 plan
    Matt Zuga
    CFO & Chief Business Officer · sold 6,888 at $1.82
    13K
    3.2% of stake
  • Jan 810b5-1 plan
    Russell Barton
    Chief Operating Officer · sold 3,530 at $1.86
    7K
    2.8% of stake
  • Jan 7 – 810b5-1 plan
    James J. Doherty
    President and CDO · sold 8,167 at avg $1.86
    15K
    13% of stake
  • Jan 710b5-1 plan
    Amy Schacterle
    Chief Regulatory Officer · sold 1,097 at $1.98
    2K
    12% of stake
  • Jan 5 – 710b5-1 plan
    Matt Zuga
    CFO & Chief Business Officer · sold 14,905 at avg $1.98
    29K
    6.4% of stake
  • Jan 5 – 710b5-1 plan
    Daniel Joseph Oconnell
    Chief Executive Officer · sold 47,506 at avg $1.99
    94K
    7.1% of stake
  • Jan 5 – 710b5-1 plan
    Derek M Meisner
    Chief Legal Officer & Corp Sec · sold 26,668 at avg $1.98
    53K
    17% of stake
  • Jan 5 – 710b5-1 plan
    Russell Barton
    Chief Operating Officer · sold 9,318 at avg $1.97
    18K
    6.8% of stake
  • Jan 5 – 610b5-1 plan
    Eric Siemers
    Chief Medical Officer · sold 10,834 at avg $1.97
    21K
    6.4% of stake
  • Jan 21, 2025 – Jan 23, 202510b5-1 plan
    Matt Zuga
    CFO & Chief Business Officer · sold 33,266 at avg $1.70
    57K
    13% of stake
  • Jan 21, 202510b5-1 plan
    Daniel Joseph Oconnell
    Chief Executive Officer · sold 12,619 at $1.59
    20K
    1.9% of stake
  • Jan 21, 202510b5-1 plan
    Derek M Meisner
    Chief Legal Officer & Corp Sec · sold 3,418 at $1.59
    5K
    2.1% of stake
  • Jan 21, 202510b5-1 plan
    Russell Barton
    Chief Operating Officer · sold 2,914 at $1.61
    5K
    2.1% of stake
  • Jan 21, 202510b5-1 plan
    Eric Siemers
    Chief Medical Officer · sold 3,219 at $1.59
    5K
    1.9% of stake
  • Jan 3, 202510b5-1 plan
    Daniel Joseph Oconnell
    Chief Executive Officer · sold 47,778 at $1.84
    88K
    6.6% of stake
  • Jan 3, 202510b5-1 plan
    Derek M Meisner
    Chief Legal Officer & Corp Sec · sold 11,122 at $1.84
    20K
    6.3% of stake
  • Jan 3, 202510b5-1 plan
    Russell Barton
    Chief Operating Officer · sold 7,636 at $1.86
    14K
    5.2% of stake
  • Jan 3, 202510b5-1 plan
    Matt Zuga
    CFO & Chief Business Officer · sold 13,235 at $1.84
    24K
    4.8% of stake
  • Jan 3, 202510b5-1 plan
    Eric Siemers
    Chief Medical Officer · sold 10,859 at $1.85
    20K
    5.9% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ABOS, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with ABOS

CompareIntrinsic value
PALIPalisade Bio Inc.
$0.84-9.69%20
VYGRVoyager Therapeutics Inc.
$1.53-4.97%10
FENCFennec Pharmaceuticals Inc.
$13.10-2.60%50
RGNXRegenxbio Inc.
$7.16-0.28%36
NVAXNovavax Inc.
$7.47-3.24%25
TECHBio-Techne Corporation
$72.67-0.04%41
CHRSCoherus Biosciences Inc.
$0.37-4.44%10
LCTXLineage Cell Therapeutics Inc.
$0.77-5.87%10

Held by ETFs

ABOS is in 2 US ETFs. The largest of them, with ABOS's weight in each:

Spot a number that looks wrong? Check it in ABOS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing ABOS

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.